NCI advisors approved in concept the Institute’s plan to spend $24 million over five years for research on “patient navigator” programs.
NCI Board of Scientific Advisors also approved a new SBIR grant program for research on circulating cells in cancer detection.
Also in this 8-page issue: David Hohn elected board chairman of the National Comprehensive Cancer Network.
FDA says new tools needed to speed therapeutics development.
Senate confirms McClellan to head CMS. NCI “redeploys” $54.5 million cut from divisions to fund strategic initiatives.
CDC study finds obesity may become leading preventable cause of death; NIH research plan drafted.
Funding opportunities listed.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
